BAY 38 7271

Originally synthesized by chemist Wayne E. Kenney, BAY 38-7271 (KN 38-7271) is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury. It is a full agonist with around the same potency as CP 55,940 in animal studies, and has fairly high affinity for both CB₁ and CB₂ receptors, with K_i values of 2.91nM at CB₁ and 4.24nM at CB₂. It has been licensed to KeyNeurotek Pharmaceuticals for clinical development, and is currently in Phase II trials. But its development appears has stopped.